Press kit

A selection of the Owkin team


Owkin is an AI biotechnology company on a mission to find the right treatment for every patient. By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools.

We use federated data access to unlock valuable insights from patient data while protecting patient privacy and securing proprietary data. We integrate the best of human and artificial intelligence to answer the research questions challenging biopharma and academic researchers.

Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

Media contact

Owkin’s experts are available to comment on topics related to medical research and Al.

For international media requests, please contact

For French media requests, please contact

About our founder

Thomas Clozel M.D.
Chief Executive Officer and co-founder

Thomas leads Owkin as CEO. He is a former Assistant Professor of Clinical Onco-Hematology at Hopital Henri Mondor in Paris and former member of Ari Melnick’s lab at the Weill Cornell Medical College. He ensures that patient health is prioritized when developing breakthrough medical technologies, bringing a patient-centric approach to each Owkin project.


Where is Owkin based?
What is Owkin's founding story?
What makes Owkin different?
What is federated learning?
How does Owkin ensure data privacy and security?
How does Substra protect data privacy?
How much investment has Owkin received?